^
No biomarker
Cervical Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
BRCA1 mutation + TP53 R248Q
Cervical Cancer
bevacizumab + olaparib
Sensitive
:
C4
J Med Case Rep - 2wk
No biomarker
Cervical Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
Zirabev (bevacizumab biosimilar)
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Cervical Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Cervical Cancer
Bevax (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
paclitaxel + topotecan
Sensitive
:
A2
No biomarker
Cervical Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Cervical Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
carboplatin
Sensitive
:
A2
No biomarker
Cervical Cancer
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Cervical Cancer
pemetrexed
Sensitive
:
A2
No biomarker
Cervical Cancer
mitomycin
Sensitive
:
A2
No biomarker
Cervical Cancer
irinotecan
Sensitive
:
A2
No biomarker
Cervical Cancer
ifosfamide
Sensitive
:
A2
No biomarker
Cervical Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Cervical Cancer
docetaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
topotecan
Sensitive
:
A2
NTRK3 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK3 fusion
Cervical Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Cervical Cancer
larotrectinib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our